NetworkNewsWire Announces Publication on Alternatives to Nicotine Delivery

Loading...
Loading...

NEW YORK, Jan. 10, 2018 (GLOBE NEWSWIRE) -- via NetworkNewsWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. LXRP, a client of NNW that has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. 

The publication, titled, "Intriguing Research into Pathways to Limit Nicotine, Quit Cigarette Use," reviews solutions by several public companies, including tobacco industry leaders, designed to help deliver nicotine without the harmful smoke of cigarettes.

To view the full publication, visit: https://www.networknewswire.com/intriguing-research-pathways-limit-nicotine-quit-cigarette-use/

Lexaria is accelerating its research focus on nicotine following its patent grant and is preparing formulations of edible forms of nicotine using the DehydraTECH™ technology. These formulations are currently completing quality control testing prior to in vivo absorption and tolerability testing. A third-party laboratory is expected to perform the first nicotine edible tests in February 2018. Imagine an edible nicotine-infused product that: masks unwanted tastes, eliminating the need for sugar-filled edibles; reduces the time of onset with effects felt within 15-20 minutes instead of up to an hour or more; avoids first-pass liver metabolism, which means fewer side effects; and increases bio-absorption by five to 10 times which equates to an inhaled delivery method - all while helping you quit smoking cigarettes.

The company's proprietary platform allows for the infusion of nicotine molecules within a wide range of edible food ingredients or typical capsule formats, effectively opening the door for the creation of a new product category targeting the high-demand smoking cessation market (http://nnw.fm/vmNg7). While this research is in its early stages, the market implications of maximizing Lexaria's patented molecular delivery method in such areas as nicotine delivery, non-steroidal anti-inflammatories (NSAIDs) and vitamins – all multibillion dollar industries – is significant. According to a 2016 report by Grand View Research, Inc., the global smoking cessation and nicotine de-addiction market is expected to reach over $21.8 billion by 2024. As Grand View reports, "The launch of… improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market (http://nnw.fm/Ytnr1)"

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About NetworkNewsWire 

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Loading...
Loading...

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact: 

NetworkNewsWire (NNW)
New York, New York 
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Loading...
Loading...
Posted In: BiotechPress ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...